Literature DB >> 19748666

Resistant hypertension: an unmet treatment need.

Bryan Williams1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19748666     DOI： 10.1016/S0140-6736(09)61600-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Assessment and management of resistant hypertension.

Authors:  Raj S Padwal; Simon Rabkin; Nadia Khan
Journal:  CMAJ       Date:  2014-08-18       Impact factor: 8.262

Review 2.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 3.  Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.

Authors:  Ana Paula Cabral de Faria; Rodrigo Modolo; Beatriz Vaz Domingues Moreno; Heitor Moreno
Journal:  Arq Bras Cardiol       Date:  2014-10-28       Impact factor: 2.000

Review 4.  Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review.

Authors:  Sanjay Kalra
Journal:  Cardiol Ther       Date:  2016-08-18

5.  The comparative effectiveness of fourth-line drugs in resistant hypertension: An application in electronic health record data.

Authors:  Sarah-Jo Sinnott; Liam Smeeth; Elizabeth Williamson; Pablo Perel; Dorothea Nitsch; Laurie A Tomlinson; Ian J Douglas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-16       Impact factor: 2.890

6.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

7.  Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.

Authors:  Cong Chen; Xue-Ying Zhu; Dong Li; Qian Lin; Kun Zhou
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.